Lipids & metabolic liver disease
Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease
Authors' conclusion
In dysmetabolic patients HOMA-IR and LAP showed the best accuracy in detecting MASLD. The possible use of lipid-based IR markers in stratifying the CV risk in patients with MASLD needs further validation in larger cohorts.
Study context
- Population
- Dysmetabolic patients evaluated for MASLD; age 55.6 ± 12.1 years, 39.4% women; 82.8% had MASLD
- Participants
- 772 patients
- Comparison
- Insulin resistance (IR) markers for detecting MASLD and predicting cardiovascular events (CVEs)
- Primary endpoint
- Accuracy (ROC AUC) of IR markers for detecting MASLD
Primary result
As reported in the abstract
Detection of MASLD (AUC)
| Group | AUC |
|---|---|
| Homeostatic Model Assessment for IR (HOMA-IR) | 0.792 |
| Lipid Accumulation Product (LAP) | 0.787 |
| Visceral Adiposity Index (VAI) | 0.731 |
| Triglycerides-Glycemia (TyG) index | 0.723 |
| TG/HDL-C | 0.721 |
AUC
Homeostatic Model Assessment for IR (HOMA-IR)0.792
Lipid Accumulation Product (LAP)0.787
Visceral Adiposity Index (VAI)0.731
Triglycerides-Glycemia (TyG) index0.723
TG/HDL-C0.721
Further findings
| Outcome | TyG index | LAP | TG/HDL-C | VAI |
|---|---|---|---|---|
| Prediction of CVEs in MASLD patients (AUC) · median follow-up 48.7 (25.4-75.8) months | ||||
| AUC | 0.630 | 0.626 | 0.614 | 0.590 |
- Prediction of CVEs in MASLD patients (AUC) — MASLD patients with CVEs
- 53 (1.8%/year)
Prediction of CVEs in MASLD patients (AUC) · median follow-up 48.7 (25.4-75.8) months
- Comparable, modest predictive values for CVE risk
Original publication
Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease. Cardiovasc Diabetol. Published 20 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →